Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615499 | 1.00 | DRD2 (0.43) | DRD2HRH3SLC6A4NOS3NOS1 | |
| SCHEMBL22918689 | 0.94 | HRH3 (0.47) | DRD2HRH3SLC6A4NOS3NOS1 | |
| SCHEMBL29615464 | 0.94 | HRH3 (0.47) | DRD2HRH3SLC6A4NOS3NOS1 | |
| SCHEMBL22918728 | 0.79 | LTA4H (0.54) | NOS3NOS1NOS2LTA4HSMN1; SMN2 | |
| SCHEMBL29615365 | 0.79 | LTA4H (0.54) | NOS3NOS1NOS2LTA4HSMN1; SMN2 | |
| SCHEMBL22919001 | 0.79 | LTA4H (0.57) | LTA4HSMN1; SMN2 | |
| SCHEMBL29615643 | 0.79 | LTA4H (0.57) | LTA4HSMN1; SMN2 | |
| SCHEMBL2023773 | 0.77 | MEN1 (0.55) | HRH3SLC6A4NOS3NOS1NOS2 | |
| SCHEMBL29868557 | 0.77 | HRH3 (0.39) | DRD2HRH3SLC6A4ESR1ESR2 | |
| SCHEMBL21052632 | 0.76 | HRH3 (0.47) | DRD2HRH3SLC6A4ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-23 | — | — | US | disclosed |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| EP-4003992-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174293-A | 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021013864-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013864-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | CHUK, CNKSR1, KIT | DRD2 3107/4885HRH3 163/4885SLC6A4 4447/4885 |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | NCOA3, NCOR1, NCOA4 | DRD2 3487/4885HRH3 102/4885SLC6A4 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.